Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Global Experts Meeting on Infectious Diseases

Tokyo, Japan

Shi Ming-Der

Shi Ming-Der

Kaohsiung Veterans General Hospital

Title: Carbapenem-resistant Acinetobacter baumannii and Pseudomonas


Biography: Shi Ming-Der


Introduction: Carbapenems are a last line of defense against many drug-resistant bacterial infections. Multi-drug-resistant bacteria have been common in Taiwan hospital such as ICUs, RCW and Chronic Ward. There is also prevalence in community care institutions. It is always threaten of patient life.

Material and Methods: We reviewed 371 chronic and acute patients more than 21 days of hospitalization. The specimen sources were sputum, urine, wounds and body fluids. The identification and susceptibility test used BD Phoenix TM 100 Automatic Microbiology System.

Results: We from 285 patients and 472 samples and 441 samples (93.3%) were Pan-Drug Resistant Acinetobacter Baumannii was isolated, and from  88.4% sputum, 6.3% urine, 4.6% wounds and 0.7% body fluids, respectively. And the others, we also from

86 patients and 356 specimens and 142 specimens (40%) were Pan-Drug Resistant Pseudomonas aeruginosa was isolated, and from 95.4% sputum and 4.6% urine samples.

Conclusions: For a long time, Carbapenem antibiotics still have been the treatment of the first choice for Acinetobacter Baumannii and Pseudomonas Aeruginosa. And in the past, it has been successfully used to treat β-lactam antibiotic for Acinetobacter Baumannii and Pseudomonas Aeruginosa, now the effect of the treatment of Carbapenem for A. Baumannii and P. Aeruginosa have also been greatly reduced in. And now, many CR-AB (Carbapenem-resistant A. baumannii) and CR-PA (Carbapenem-resistant P. Aeruginosa) resistance has increased. We also find the vancomycin resistant enterococci has elevated in our hospital. Therefore, clinicians not yet confirmed patients infected with the bacterial species, if the patient condition permission, do not using antibiotics before the Medical laboratory scientist identification of bacteria and drug sensitivity test reports. So, the clinician’s has prudent choice of appropriate antibiotic treatment to prevent bacterial resistance.